Eli Lilly (LLY) experienced a significant surge of 7.2% in early trading on Wednesday. The company reported fourth-quarter revenue of $19.29 billion, marking a 43% increase, alongside an adjusted earnings per share of $7.54. Fueled by the strong performance of Zepbound and Mounjaro, Eli Lilly raised its 2026 revenue guidance to a range of $80 to $83 billion and increased its earnings per share projection to between $33.50 and $35.00.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.